Sutro Biopharma Inc. (NASDAQ:STRO)’s traded shares stood at 2.64 million during the last session, with the company’s beta value hitting 0.92. At the close of trading, the stock’s price was $5.22, to imply a decrease of -0.38% or -$0.02 in intraday trading. The STRO share’s 52-week high remains $9.75, putting it -86.78% down since that peak but still an impressive 36.21% since price per share fell to its 52-week low of $3.33. The company has a valuation of $307.61M, with an average of 0.46 million shares in intraday trading volume over the past 10 days and average of 507.24K shares over the past 3 months.
Sutro Biopharma Inc. (NASDAQ:STRO) trade information
After registering a -0.38% downside in the last session, Sutro Biopharma Inc. (STRO) has traded red over the past five days. The stock hit a weekly high of 5.93 this Friday, 03/17/23, dropping -0.38% in its intraday price action. The 5-day price performance for the stock is 1.75%, and -15.94% over 30 days. With these gigs, the year-to-date price performance is -35.40%. Short interest in Sutro Biopharma Inc. (NASDAQ:STRO) saw shorts transact 2.11 million shares and set a 2.47 days time to cover.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sutro Biopharma Inc. (STRO) estimates and forecasts
Looking at statistics comparing Sutro Biopharma Inc. share performance against respective industry, we note that the company has underperformed competitors. Sutro Biopharma Inc. (STRO) shares are -9.06% down over the last 6 months, with its year-to-date growth rate lower than industry average at -27.18% against 9.60%. Revenue is forecast to grow 25.30% this quarter before jumping 26.20% for the next one. The rating firms project that company’s revenue will grow 20.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is $14.48 million. Meanwhile, for the quarter ending Mar 2023, a total of 6 analyst(s) estimate revenue growth to $14.72 million.Earnings reports from the last fiscal year show that sales brought in $10.65 million and $5.9 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 35.90% before jumping 149.60% in the following quarter.
Sutro Biopharma Inc. has its next earnings report out between March 07 and March 13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Sutro Biopharma Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Sutro Biopharma Inc. (NASDAQ:STRO)’s Major holders
Sutro Biopharma Inc. insiders hold 5.67% of total outstanding shares, with institutional holders owning 88.47% of the shares at 93.78% float percentage. In total, 88.47% institutions holds shares in the company, led by Suvretta Capital Management, LLC. As of Sep 29, 2022, the company held over 5.02 million shares (or 8.73% of shares), all amounting to roughly $27.86 million.
The next major institution holding the largest number of shares is Blackrock Inc. with 4.01 million shares, or about 6.97% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $22.25 million.
We also have Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Sutro Biopharma Inc. (STRO) shares. Going by data provided on Sep 29, 2022, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund holds roughly 2.71 million shares. This is just over 4.71% of the total shares, with a market valuation of $15.03 million. Data from the same date shows that the other fund manager holds a little less at 1.2 million, or 2.08% of the shares, all valued at about 9.67 million.